Evidence map›Paper›PMID 41810270›Full record

ArticleInternational journal of applied & basic medical research

Cardioprotective Effects of Dapagliflozin against Isoproterenol-induced Myocardial Injury in Rats: Biochemical and Histopathological Evidence.

Mohammed M Mosaed, Naglaa A Bayomy, Ahmed M Hegazy, Saad Elshafey, Naglaa Mokhtar, Reda H Elbakary, Safya E Esmaeel, Shereen M Olama, Basem Salama, Marwa S Badawi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of applied & basic medical research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mohammed M MosaedDepartment of Anatomy, Faculty of Medicine, Northern Border University, Arar, Saudi Arabia.
Naglaa A BayomyDepartment of Anatomy, Faculty of Medicine, Northern Border University, Arar, Saudi Arabia.
Ahmed M HegazyDepartment of Anatomy, Faculty of Medicine, Northern Border University, Arar, Saudi Arabia.
Saad ElshafeyDepartment of Anatomy, Faculty of Medicine, Northern Border University, Arar, Saudi Arabia.
Naglaa MokhtarDepartment of Medical Biochemistry, College of Medicine, Northern Border University, Arar, Saudi Arabia.
Reda H ElbakaryDepartment of Histology and Cell Biology, Faculty of Medicine, Tanta University, Tanta, Egypt.
Safya E EsmaeelDepartment of Physiology, College of Medicine, Northern Border University, Arar, Saudi Arabia.
Shereen M OlamaDepartment of Medicine, Faculty of Medicine, Northern Border University, Arar, Saudi Arabia.
Basem SalamaDepartment of Community and Family Medicine, Faculty of Medicine, Northern Border University, Arar, Saudi Arabia.
Marwa S BadawiDepartment of Anatomy, Faculty of Medicine, Northern Border University, Arar, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: As a leading cause of global morbidity, myocardial infarction (MI) is a primary focus of medical research. The isoproterenol (ISO)-induced model of cardiac injury is a cornerstone of this work, providing a validated experimental system that simulates the human condition. This study investigated the cardioprotective potential of dapagliflozin (DAPA), a sodium-glucose cotransporter-2 (SGLT2) inhibitor, against ISO-induced myocardial injury in adult male rats. Materials and Methods: Thirty-two rats were divided into four groups; Control group, DAPA-only group: DAPA (1 mg/kg/day, orally, 14 days) + saline, ISO-only: Saline (orally, 14 days) + ISO (100 mg/kg/day, days 13-14) and fourth group, DAPA + ISO: pretreated with DAPA 1 mg/kg/day orally) for 14 days, followed by ISO 100 mg/kg, subcutaneously days 13-14. DAPA's protective effects against ISO-induced MI were evaluated by assessing cardiac damage by measuring serum biomarkers of heart injury while simultaneously evaluating oxidative stress through lipid peroxidation levels and antioxidant activity in cardiac tissue. Histopathological examination revealed structural changes in myocardial tissue, complemented by molecular analysis quantifying the expression of key apoptotic regulators. Results: Biochemical analysis revealed that DAPA significantly reduced ISO-induced elevations in cardiac troponin-I, creatine kinase-MB, lactate dehydrogenase, and oxidative stress markers; malondialdehyde, superoxide dismutase, and reduced glutathione. DAPA also attenuated inflammatory cytokines: tumor necrosis factor-alpha and interleukin-6 (IL-6). Histopathological examination of heart tissues demonstrated that DAPA mitigated ISO-induced myocardial necrosis and inflammatory infiltration, preserving cardiac architecture. Moreover, DAPA downregulated the pro-apoptotic protein (Bax) expression and upregulated the anti-apoptotic protein (Bcl2) levels in the heart. Conclusions: These findings suggest that DAPA exerts multimodal cardio-protection beyond its antidiabetic action, positioning it as a promising adjunct therapy for ischemic heart disease. Further clinical studies are warranted to validate its translational potential.

Indexed as

AntioxidantsBaxBcl2 expressiondapagliflozinmyocardial injury

Identifiers

PMID41810270
PMCPMC12970755

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.